Sodium Deposition in Soft Tissues of Patients With Kidney Disease

Study Lead

Dr. Christopher McIntyre

London Health Sciences Centre


Kidneys have a key role in sodium hemostasis through their excretory function. In patients with chronic kidney disease (CKD), kidney function is impaired; thus, suggesting that sodium handling is abnormal in this setting with long-term sodium loading (from oral intake) and lack of adequate urinary excretion. Yet, sodium concentration needs to stay relatively constant to prevent fatal intra-cellular accumulation, which would result in cell injury and death. In hemodialysis patients, at least a part of this extra sodium is non-osmotically active and deposited in the skin, muscle, and skeleton.

Furthermore, it has become increasingly recognized that sodium (once accumulated in tissues) is directly pro-inflammatory, affecting the innate immune system by regulating the activity of macrophages in skin. This linkage between sodium and inflammation indicates a potential link between sodium deposition and uremic symptoms experienced by patients.

There have been no studies to date examining the sodium deposition in the skin, muscle, and skeleton of patients with different kidney function and renal replacement therapy.

This is a pilot study involving a single center recruiting patients from the prevalent maintenance hemodialysis, peritoneal dialysis , CKD stage 1-5, and heart failure populations of London, Ontario, compared to healthy controls. Once recruited, participants will undergo one study visit with the potential of up to two follow-up visits (on a non-dialysis day for hemodialysis patients). Participants will be followed for up to two years after the first study visit. Each session will include symptom questionnaires, the five times sit to stand and 60-second chair stand test (excluding all children), blood pressure and heart rate measurements, blood work (excluding healthy children and adolescents), urine sampling (excluding those on dialysis), an echocardiogram (excluding healthy controls), and an MRI scan of the lower leg detecting sodium content.


Inclusion Criteria:

  • Age greater than or equal to 6 years
  • For patients on maintenance hemodialysis or peritoneal dialysis: more than 3 months duration of therapy
  • For patients with CKD stage 1-5: CKD stage 1-5 and no indications to start dialysis
  • For heart failure patients: with or without renal dysfunction
  • For healthy controls: lack of kidney disease, heart failure, liver cirrhosis, and peripheral edema

For subsequent visits (must meet 1 of the below indicators):

  • Change in dialysis prescription
  • Change in renal replacement therapy modality
  • Change in medication
  • Parathyroidectomy
  • Intervention added to or removed from dialysis (i.e. such as but not limited exercise, cooling, and ischemic preconditioning)

Exclusion Criteria:

  • Pregnant, breastfeeding or intending pregnancy
  • Unable to give consent or understand written information
  • Contraindication to MRI study

Type of Participation

Clinical Trial


Chronic Kidney Disease


Hemodialysis, Peritoneal Dialysis





Related studies

  • Take part in one hemodialysis session to evaluate Qidni Labs’ nearly waterless and portable dialysis system

    Overview: Qidni Labs is inviting up to 30 patients with kidney failure to take part in research studying the “Qidni/D”, an investigational hemodialysis device, as a possible treatment for kidney failure.

    Study type: Clinical Trial

    May 16, 2023

  • Person-centered integrated care delivery for patients with chronic kidney disease and multimorbidity in the primary care setting and primary-nephrology care interface

    Overview: Participants are invited to complete a 15-minute survey with questions about their experience with kidney care in Alberta.

    Study type: Survey

    May 16, 2023

  • Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE)

    Overview: The purpose of this study is to determine if spironolactone reduces death or hospitalization for heart failure and is well tolerated in patients that require dialysis.

    Study type: Clinical Trial

    April 28, 2023